Alexza files Staccato loxapine in the US
This article was originally published in Scrip
Alexza Pharmaceuticals has filed an NDA with the US FDA for Staccato loxapine (AZ-004), an inhaler for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.